Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colitis 1Burkitt Lymphoma 1

Interventions

Methylprednisolone 3Social Determinants of Health 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegaspargase 1Vincristine 1Temozolomide 1Radiotherapy 1Prednisone 1Prednisolone 1Pharmaceutical Services 1Methylprednisolone Hemisuccinate 1Methotrexate 1Mercaptopurine 1Leucovorin 1Irinotecan 1Infliximab 1Hydrocortisone 1Fecal Microbiota Transplantation 1Etoposide 1Drug Therapy 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Cytarabine 1Cyclophosphamide 1Cefixime 1CTLA-4 Antigen 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Methylprednisolone Hemisuccinate × 1 year × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡